Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M File

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
Diagnostic Microbiology and Infectious Disease|September 30, 2018
Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and EuropeDavid B Huang, Sophie Magnet, Stefania De Angelis, et al.
Journal of the American Veterinary Medical Association|May 4, 2022
Hostage to history - questioning the duration of systemic antimicrobial therapy for the treatment of canine superficial bacterial folliculitisCandace A Sousa, Jenifer Chatfield, Thomas M File, et al.
International Journal of Antimicrobial Agents|January 11, 2012
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisationSusan C Nicholson, Tobias Welte, Thomas M File, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaThomas M File, Donald E Low, Paul B Eckburg, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaDonald E Low, Thomas M File, Paul B Eckburg, et al.
International Journal of Antimicrobial Agents|October 7, 2008
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibioticThomas M File, Scott V Monte, Jerome J Schentag, et al.
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Postgraduate Medicine|November 27, 2009
Higher pneumococcal disease vaccination rates needed to protect more at-risk US adultsSusan J Rehm, Monica M Farley, Thomas M File, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) TrialThomas M File, Lisa Goldberg, Anita Das, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2019
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) TrialThomas M File, Lisa Goldberg, Anita Das, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Diagnostic Microbiology and Infectious Disease|September 30, 2018
Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and EuropeDavid B Huang, Sophie Magnet, Stefania De Angelis, et al.
Journal of the American Veterinary Medical Association|May 4, 2022
Hostage to history - questioning the duration of systemic antimicrobial therapy for the treatment of canine superficial bacterial folliculitisCandace A Sousa, Jenifer Chatfield, Thomas M File, et al.
International Journal of Antimicrobial Agents|January 11, 2012
A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisationSusan C Nicholson, Tobias Welte, Thomas M File, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaThomas M File, Donald E Low, Paul B Eckburg, et al.
The Journal of Antimicrobial Chemotherapy|April 13, 2011
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumoniaDonald E Low, Thomas M File, Paul B Eckburg, et al.
International Journal of Antimicrobial Agents|October 7, 2008
A disease model descriptive of progression between chronic obstructive pulmonary disease exacerbations and community-acquired pneumonia: roles for underlying lung disease and the pharmacokinetics/pharmacodynamics of the antibioticThomas M File, Scott V Monte, Jerome J Schentag, et al.
International Journal of Antimicrobial Agents|May 22, 2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infectionsDavid B Huang, G Ralph Corey, Thomas L Holland, et al.
Postgraduate Medicine|November 27, 2009
Higher pneumococcal disease vaccination rates needed to protect more at-risk US adultsSusan J Rehm, Monica M Farley, Thomas M File, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2019
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) TrialThomas M File, Lisa Goldberg, Anita Das, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 19, 2019
Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) TrialThomas M File, Lisa Goldberg, Anita Das, et al.
Pageof 16